[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","commit":"925a04b429","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a third batch of thirty approved products","file":"src/data/spikes/breast-hr-positive.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fulvestrant\" }]"}]},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/breast-hr-positive.ts","type":"changed","fields":[{"field":"tldr","before":"\"A monthly injection that destroys the oestrogen receptor; the standard partner for many targeted drugs after hormone therapy stops working.\"","after":"\"Fulvestrant is a monthly injection that destroys the oestrogen receptor; it is the standard partner for many targeted drugs after hormone therapy stops working.\""}]},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","commit":"f8e98e6f47","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: HR+/HER2- and HER2+ breast cancer to TNBC depth (structured trial outcomes, dosing, toxicity, regulatory events)","file":"src/data/spikes/breast-hr-positive.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"cancers"},{"field":"trials"}]}]